Metagenomi Reports Strong Q2 2025 Financial Results

Metagenomi, Inc. ( (MGX) ) has shared an announcement.

Metagenomi, Inc. reported its second quarter 2025 financial results and business updates, highlighting significant advancements in its gene editing technologies. The company presented three abstracts at the American Society of Gene & Cell Therapy, showcasing early proof-of-concept data for its gene editing technologies, and announced a strong cash position of $205 million, expected to support operations into 2027. Metagenomi continues to advance its MGX-001 program for Hemophilia A and its collaboration with Ionis in cardiometabolic indications, while also enhancing its board with the appointment of Laurence Reid, Ph.D. The company is focused on operational efficiency and investment in its pipeline and AI-driven metagenomics platform.

The most recent analyst rating on (MGX) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.

Spark’s Take on MGX Stock

According to Spark, TipRanks’ AI Analyst, MGX is a Neutral.

Metagenomi, Inc. benefits from strong revenue growth and recent technological advancements, but faces challenges with profitability and cash flow. The stock’s technical indicators show positive momentum, yet valuation metrics highlight ongoing financial losses. The company’s strategic advancements in genome editing and a solid cash position provide a positive outlook.

To see Spark’s full report on MGX stock, click here.

More about Metagenomi, Inc.

Metagenomi, Inc. is a precision gene editing company that utilizes artificial intelligence and machine learning to develop potentially curative genome editing therapeutics. The company’s metagenomics-derived gene editing toolbox has analyzed over 7.4 billion proteins, targeting various genetic mutations across the human genome. Metagenomi’s platform includes technologies for ultra-small nucleases, base editors, and large gene integrations using CRISPR-associated transposase and RNA-Mediated Integration Systems. Their lead program focuses on Hemophilia A, aiming to provide lifelong protection from bleeding events and joint damage.

Average Trading Volume: 641,800

Technical Sentiment Signal: Sell

Current Market Cap: $68.41M

Find detailed analytics on MGX stock on TipRanks’ Stock Analysis page.